RECRUITING

Using Aspirin to Improve Immunological Features of Ovarian Tumors

Conditions

Ovarian Cancer Fallopian Tube Cancer Peritoneal Cancer

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of the study is to evaluate the effectiveness of aspirin with neoadjuvant chemotherapy for decreasing markers of immune suppression in the tumor at interval debulking surgery, in women with diagnosed ovarian, fallopian tube, or peritoneal carcinoma

Official Title

Pilot Study to Assess the Efficacy of Aspirin to Improve Immunological Features of Ovarian Tumors

Quick Facts

Study Start:2021-11-02

Study Completion:2025-05

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05080946

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:FEMALE

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Participants that are greater than or equal to 18 years of age * For U.S. sites, patients can read and understand English or Spanish; for Canadian site, participants can read and understand English or French * Histology confirmed, or clinical suspicion of, invasive epithelial ovarian, fallopian tube, or peritoneal carcinoma. Must be grade 2 or 3 or high (where high is defined as grade 2/3). All histologies including serous, endometrioid, clear cell sarcoma, or carcinosarcoma histology is acceptable. Mixed histology also acceptable. * Treatment naïve for this cancer diagnosis * Planned for neoadjuvant chemotherapy (platinum-based doublet with taxane +/- anti-VEGF antibody) for at least 3 but no more than 5 cycles followed by an interval debulking surgery. \[Note: this study evaluates response while on neoadjuvant treatment. The final collection of specimen and questionnaire is at the time of surgery and immediate post-operative state. Therefore, there are no eligibility criteria related to treatment in the adjuvant setting (e.g., intraperitoneal treatment) and adjuvant therapy should proceed as the physician deems appropriate.\] * Measurable disease as defined by RECIST 1.1, CT scan (with or without contrast) within 12 weeks of study enrollment. * Eastern Cooperative Oncology Group (ECOG) performance status of 0,1, or 2 * Able to provide tissue biopsy (core or excisional) sufficient for diagnosis and biomarker analysis, may use outside archival tissue if available. * If currently using anti-coagulation medication, no contraindication for temporary stoppage of use during the study based on physician judgement * Willing and able to swallow pills without difficulty * Un-transfused platelet count \> 100,000 cells/μL * Willing and able to participate in all required evaluations and procedures in this study protocol (e.g. undergoing treatment, scheduled visits and examinations, serum testing, questionnaires, pill log/diary) * Absolute neutrophil count \> 1.5 x 109 cells/L * Hemoglobin \> 9.0 g/dL, may use transfusions and the value can be post-transfusion * Estimated creatinine clearance of \> 30 mL/min, calculated using the formula Cockcroft-Gault \[(140-age) x Mass (kg)/(72 x creatinine mg/dL)\] x 0.85 for female * No severe hepatic impairment defined as AST or ALT elevation \< 2.5 x institutional ULN, unless liver metastasis is present \< 5 x ULN	* Definite contraindication for either aspirin use or stopping current aspirin use based on physician's clinical judgment * History of vascular event in the last 12 months (e.g., myocardial infarction or unstable angina, stroke, coronary artery angioplasty or stenting, coronary artery bypass graft, relevant \[serious or significant\] arrhythmias, significant vascular disease, congestive heart failure or vascular interventions). * History of hypertensive crisis and/ or uncontrolled HTN, systolic blood pressure \> 150 mmHg; diastolic blood pressure \> 90mmHg. Participants must have blood pressure \< 150/90 mmHg taken in a clinic setting by a medical professional within 2 weeks prior to starting study. * Current or history of ulcers which prohibits aspirin consumption, severe hepatic failure, or acute or chronic renal disease where aspirin use is contraindicated * History of gastrointestinal or genitourinary bleeding or other bleeding diathesis or coagulopathy within 6 months prior to enrollment of study * Uncontrolled erosive esophagitis requiring 2 or more treatments * Other cancer diagnosis in the last 3 years other than non-melanoma skin cancer * Autoimmune disorder requiring systemic therapy * Chronic steroid use defined as 3 weeks in the past year or any length of time in the past 30 days. * Other aspirin or NSAID hypersensitivities or contraindications (e.g. allergy) * History of bariatric surgery * Currently pregnant at the Screening visit or planning on becoming pregnant during the study period * Participant is unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with study medication. * Metabolism CYP2C9, known G6PD deficient patients

Inclusion Criteria

Exclusion Criteria

* Participants that are greater than or equal to 18 years of age
* For U.S. sites, patients can read and understand English or Spanish; for Canadian site, participants can read and understand English or French
* Histology confirmed, or clinical suspicion of, invasive epithelial ovarian, fallopian tube, or peritoneal carcinoma. Must be grade 2 or 3 or high (where high is defined as grade 2/3). All histologies including serous, endometrioid, clear cell sarcoma, or carcinosarcoma histology is acceptable. Mixed histology also acceptable.
* Treatment naïve for this cancer diagnosis
* Planned for neoadjuvant chemotherapy (platinum-based doublet with taxane +/- anti-VEGF antibody) for at least 3 but no more than 5 cycles followed by an interval debulking surgery. \[Note: this study evaluates response while on neoadjuvant treatment. The final collection of specimen and questionnaire is at the time of surgery and immediate post-operative state. Therefore, there are no eligibility criteria related to treatment in the adjuvant setting (e.g., intraperitoneal treatment) and adjuvant therapy should proceed as the physician deems appropriate.\]
* Measurable disease as defined by RECIST 1.1, CT scan (with or without contrast) within 12 weeks of study enrollment.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0,1, or 2
* Able to provide tissue biopsy (core or excisional) sufficient for diagnosis and biomarker analysis, may use outside archival tissue if available.
* If currently using anti-coagulation medication, no contraindication for temporary stoppage of use during the study based on physician judgement
* Willing and able to swallow pills without difficulty
* Un-transfused platelet count \> 100,000 cells/μL
* Willing and able to participate in all required evaluations and procedures in this study protocol (e.g. undergoing treatment, scheduled visits and examinations, serum testing, questionnaires, pill log/diary)
* Absolute neutrophil count \> 1.5 x 109 cells/L
* Hemoglobin \> 9.0 g/dL, may use transfusions and the value can be post-transfusion
* Estimated creatinine clearance of \> 30 mL/min, calculated using the formula Cockcroft-Gault \[(140-age) x Mass (kg)/(72 x creatinine mg/dL)\] x 0.85 for female
* No severe hepatic impairment defined as AST or ALT elevation \< 2.5 x institutional ULN, unless liver metastasis is present \< 5 x ULN

* Definite contraindication for either aspirin use or stopping current aspirin use based on physician's clinical judgment
* History of vascular event in the last 12 months (e.g., myocardial infarction or unstable angina, stroke, coronary artery angioplasty or stenting, coronary artery bypass graft, relevant \[serious or significant\] arrhythmias, significant vascular disease, congestive heart failure or vascular interventions).
* History of hypertensive crisis and/ or uncontrolled HTN, systolic blood pressure \> 150 mmHg; diastolic blood pressure \> 90mmHg. Participants must have blood pressure \< 150/90 mmHg taken in a clinic setting by a medical professional within 2 weeks prior to starting study.
* Current or history of ulcers which prohibits aspirin consumption, severe hepatic failure, or acute or chronic renal disease where aspirin use is contraindicated
* History of gastrointestinal or genitourinary bleeding or other bleeding diathesis or coagulopathy within 6 months prior to enrollment of study
* Uncontrolled erosive esophagitis requiring 2 or more treatments
* Other cancer diagnosis in the last 3 years other than non-melanoma skin cancer
* Autoimmune disorder requiring systemic therapy
* Chronic steroid use defined as 3 weeks in the past year or any length of time in the past 30 days.
* Other aspirin or NSAID hypersensitivities or contraindications (e.g. allergy)
* History of bariatric surgery
* Currently pregnant at the Screening visit or planning on becoming pregnant during the study period
* Participant is unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with study medication.
* Metabolism CYP2C9, known G6PD deficient patients

Contacts and Locations

Study Contact

Tiffany Shiles

CONTACT

813-745-2948

Tiffany.Shiles@moffitt.org

Principal Investigator

Jing-Yi Chern, MD

PRINCIPAL_INVESTIGATOR

Moffitt Cancer Center

Study Locations (Sites)

Moffitt Cancer Center

Tampa, Florida, 33612

United States

University of Virginia Comprehensive Cancer Center

Charlottesville, Virginia, 22903

United States

Inova Schar Cancer Institute

Fairfax, Virginia, 22031

United States

Collaborators and Investigators

Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Jing-Yi Chern, MD, PRINCIPAL_INVESTIGATOR, Moffitt Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-11-02

Study Completion Date2025-05

Study Record Updates

Study Start Date2021-11-02

Study Completion Date2025-05

Terms related to this study

Additional Relevant MeSH Terms

Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cancer